The 340B rebate pilot
From 1 January 2027, a drug maker with an approved plan may give the 340B price on certain drugs as a rebate after the sale, where today it is a discount at the time of purchase. This page sets out what the federal notice says: which drugs, what a covered entity does and by when, and the limits on a drug maker.
What changes
A discount up front
A covered entity buys a 340B drug at the 340B price.
A rebate after the sale
For a drug in the pilot, the covered entity orders at the maker’s list price, the wholesale acquisition cost (WAC). After the drug is dispensed it sends claim data to the maker’s platform, and the maker pays back the difference between WAC and the 340B ceiling price on the day of dispense.
The pilot was opened by the Health Resources and Services Administration (HRSA), the agency that runs 340B, in a notice published on 3 August 2026. It runs for at least one year. A maker may use rebates only with the agency’s approval of its plan, and only for the drugs below. The agency may take a maker’s approval away at any time if the maker does not keep to the rules.
The four clocks
- 90daysNotice a drug maker’s plan must give covered entities before it starts, with instructions for registering on its data platform.
- 45daysThe least time a covered entity has, from the day a drug is dispensed, to send the claim data.
- 10daysTime the maker has to pay the rebate, or to deny it with documents, once the data is complete.
- 15daysGrace period before the start day: rebates may be asked for up to 2 packages already dispensed and not yet replenished.
All four are counted in calendar days. If a submission comes back as incomplete, the 10 days start again when the missing data is sent.
Which drugs
The pilot covers the drugs selected for Medicare price negotiation for 2026 and 2027, whoever pays for the prescription and whatever it is prescribed for. A drug is in the pilot only while its negotiated Medicare price is in effect, only for the package codes (NDC-11) on the list below, and only where its maker has an approved plan.
Selected for 202610 drugs
- Eliquisapixaban
- Enbreletanercept
- Entrestovalsartan / sacubitrilat
- Farxigadapagliflozin
- Imbruvicaibrutinib
- Januviasitagliptin
- Jardianceempagliflozin
- NovoLog, NovoLog FlexPen, NovoLog PenFill, Fiasp, Fiasp FlexTouch, Fiasp PenFillinsulin aspart, human
- Stelaraustekinumab
- Xareltorivaroxaban
Selected for 202715 drugs
- Austedo, Austedo XRdeutetrabenazine
- Breo Elliptafluticasone; vilanterol
- Calquenceacalabrutinib
- Ibrancepalbociclib
- Janumet, Janumet XRmetformin; sitagliptin
- Linzesslinaclotide
- Ofevnintedanib
- Otezlaapremilast
- Ozempic, Rybelsus, Wegovysemaglutide
- Pomalystpomalidomide
- Tradjentalinagliptin
- Trelegy Elliptafluticasone; umeclidinium; vilanterol
- Vraylarcariprazine
- Xifaxanrifaximin
- Xtandienzalutamide
From the Medicare Drug Price Negotiation Selected Drug List of the Centers for Medicare & Medicaid Services (CMS), version of 17 January 2025, which also gives every NDC-11. CMS updates the list, so check its page on the negotiation program for the current one.
What a covered entity does
The notice sets these out as terms a maker’s plan must contain before the agency approves it.
- Hears from the maker first. A maker must give 90 calendar days’ notice before it starts, with instructions for registering on its data platform. The maker pays every cost of the platform.
- Orders the way it does now. Orders go through the channels already in place, such as a 340B wholesaler account, at WAC.
- Sends the claim data. It has at least 45 calendar days from the day of dispense, with allowances for extenuating circumstances and for a claim whose 340B status changes.
- Is paid, or is given a reason. The maker must pay the rebate, or deny it with documents, within 10 calendar days of a complete submission. A covered entity must be allowed to send data again when a request is found incomplete.
- Gets a price file every quarter. The maker must give covered entities a 340B price file for each NDC-11, for billing Medicaid at the price after the rebate and for sliding fee scales.
- Can take a denial to the agency. A covered entity may raise a denial it disputes with HRSA.
HRSA estimates that reporting claims will cost covered entities $523,345,680 a year in all, about $34,320 for each of 15,249 covered entities (its count on 1 April 2026) on average, and says the cost may vary by kind of entity.
The limits on a drug maker
- A rebate may not be denied over concerns about diversion, Medicaid duplicate discounts or eligibility, or because the maker believes too little was bought at WAC. The maker must raise those concerns with HRSA, or through the audits and dispute process the 340B law already has.
- The data a maker asks for should be limited to the claim fields listed below. The notice says purchasing data and encounter data should not be requested at this time.
- The data should not be used for anything but the pilot. That covers collecting, combining, sharing or licensing it, by the maker or by the platform.
- The maker bears every cost of the data platform.
- A maker may not start a plan without the agency’s approval, and a change to an approved plan goes to the agency for approval first.
A maker may deny a rebate where it gives its reason and the documents for it. The notice’s examples are a claim on which the drug’s negotiated Medicare price already applies, and a claim on which another covered entity has already been given a 340B rebate.
The data a maker may ask for
For a pharmacy claim
- Date of Service
- Date Prescribed
- Rx number
- Fill number
- NDC-11
- Quantity Dispensed
- Prescriber ID
- Service Provider ID
- 340B ID
- RX BIN
- RX PCN
For a medical claim
- Date of Service
- Claim Line Number
- Claim Number
- Unit of Measure
- NDC-11
- Quantity
- Rendering Physician ID
- Service Provider ID
- 340B ID
- Health Plan Name
- Health Plan ID
- Health Plan ID Qualifier (if available)
The fields are named as the notice prints them. For a patient with no insurance, or who pays cash, the BIN, PCN and health plan fields may be marked “CASH”.
The dates
Notice published91 FR 48883
Notice Regarding 340B Rebate Model Pilot Program
Health Resources and Services AdministrationFederal Register
Date set by a notice91 FR 48883
Drug makers' plans for the rebate pilot were due
Notice Regarding 340B Rebate Model Pilot Program
Health Resources and Services AdministrationFederal Register
Date set by a notice91 FR 48883
The day by which the agency said it would approve drug makers' plans for the rebate pilot, if any
Notice Regarding 340B Rebate Model Pilot Program
Health Resources and Services AdministrationFederal Register
Takes effect91 FR 48883
Notice Regarding 340B Rebate Model Pilot Program
Health Resources and Services AdministrationFederal Register
Date set by a notice91 FR 48883
The day by which the agency says it will publish its evaluation of the rebate pilot's first year
Notice Regarding 340B Rebate Model Pilot Program
Health Resources and Services AdministrationFederal Register
HRSA also says it will publish summaries of what it finds as the pilot runs, and that it expects each maker to give it a copy of its approved plan to post on its website.
Also on 1 January 2027
Other federal rules with a date on the same day that touch 340B.
- 91 FR 62936Global Benchmark for Efficient Drug Pricing (GLOBE) ModelFinal ruleSets up the GLOBE Model, a Medicare Part B drug rebate test, and leaves 340B units out of its rebate count. It keeps the existing 340B claims modifier, TB, to find those units and says 340B itself, including how its price is calculated, is outside the model.
- 91 FR 70284Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available SlotsFinal ruleSets Medicare hospital outpatient payment for drugs bought under 340B at average sales price minus 28 percent for 2027, where minus 33.4 percent had been proposed. Rural sole community hospitals, children's hospitals and the cancer hospitals paid outside the prospective payment system are exempt. Payments for other services at hospitals subject to the 340B remedy offset are reduced by 2.0 percentage points.
- 91 FR 70992Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate ProgramFinal ruleRequires 340B covered entities to report Medicare Part D 340B claim data every quarter to a 340B repository run by the Centers for Medicare & Medicaid Services, for claims from January 1, 2027. The first required submission is due September 30, 2027.
How it got here
- 1 August 2025. HRSA opened a first rebate pilot (90 FR 36163), to start on 1 January 2026 for the drugs selected for 2026.
- 29 December 2025. A federal court in Maine paused that pilot across the country, three days before its start. The agency withdrew the pilot, and on 10 February 2026 the court set its notice aside.
- 17 February 2026. HRSA asked the public (91 FR 7287) whether to use rebates in 340B and how. It counts 2,475 comments.
- 3 August 2026. HRSA published the revised pilot (91 FR 48883), the one this page describes.
In Congress, H.R. 10770, the 340B Rebate Model Delay Act, was introduced on 9 October 2026. It would bar, through 31 December 2028, agreements under which a covered entity pays more than the ceiling price when it buys a drug, and hold back the 340B Rebate Model Pilot Program for the same period.
The notice is the authority, and it can be changed. This page says what the notice says. It does not say which makers have an approved plan, and it does not follow court cases: a court stopped the first pilot days before its start. Read the notice, and check with HRSA, before you plan around a date.
See something missing or out of date? Tell us.